



ODI Pharma

Half-year report

July 2022 – December 2022

23rd Feb 2023

ODI PHARMA HALF-YEAR REPORT

In this half-year report, the following definitions apply, unless stated otherwise: The “Company” or “ODI Pharma” refers to ODI Pharma AB with org. number (Swedish corporate registration number) 559223-1392. Amount in brackets refers to the corresponding period in the previous year.

ODI Pharma AB was formed on the 23rd of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG and ODI Pharma Polska Sp. z o.o. The group was established on the 28th of June 2018 when ODI Pharma Schweiz AG acquired the shares in ODI Pharma Polska Sp. z o.o.

Second quarter (2022-10-01 – 2022-12-31)

The Group's net sales amounted to SEK 73,276 (458,620).

The Group's loss after financial items amounted to SEK -1,735,431 (-1,401,502).

Result per share amounted to SEK -0.11 (-0.09).*

Six months (2022-07-01 – 2022-12-31)

The Group's net sales amounted to SEK 101,282 (458,620).

The Group's loss after financial items amounted to SEK -3,419,942 (-2,576,890).

Result per share amounted to SEK -0.22 (-0.17).*

The solidity as of 2022-12-31 was 81% (93%).**

** The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 31st of December 2022, amounted to 15 220 000 (15 220 000) shares. The result per share based on the average number of shares of 15,220,000 (15,220,000) amounts to SEK -0.22 (-0.17) for the first six months 2022-07-01 to 2022-12-31.*

*** Solidity: Equity divided by total capital.*

Highlights during Q2

- December – ODI Pharma held its Annual General Meeting. A summary of the resolutions is available on ODI Pharma's website (<https://www.odipharma.com/>).

Highlights after the end of the period

- January – ODI Pharma received approval from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) in Poland for its Marketing Authorization Holder (MAH) application. The approval means that ODI Pharma has the right to distribute and sell its medical cannabis products on the Polish market.

MARKET VIEW OF ODI PHARMA

ODI Pharma continues to share observations of trends in the cannabis industry for current and potential investors.

As we have issued the press release that ODI Pharma has received the Marketing Authorization in Poland and we are now in a position to supply medicine to pharmacy, we are very satisfied with the developments of the Polish medical cannabis market. Market data shows that the desire for medical cannabis for treatment of multiple symptoms is growing quickly in the country and that there is currently not enough product to meet the demand. We find this as a very exciting position to be in and we are working to our fullest to meet the demand of patients in need over the coming quarters. We do also understand that competition is also working hard, and we need to do all that we can to establish our brand as quickly as possible.

We have also re-ignited some study of delivery devices for intake of medical cannabis and alternative delivery forms of cannabis as we believe that this will be an important part of the cannabis industry moving forward. There are medical devices that are quite expensive; however, we believe that this is a critical step to the evolution of the business to find less expensive measured intake. Of course, in the future, there will be an evolution to extracts over flower, however, for acute pain management and effects the flower is still the optimal intake mechanism, and, in our view, it will remain an important part of helping patients.

Europe wide, since the last report there has not been any material regulatory changes that we identify, however, the slow grind of an evolution of an industry takes place daily. In reading the updates, what does continue to be exciting is the number of resources being placed into cannabis research with depression, anxiety, ADHD, and insomnia - just to mention a small percentage of the studies. Simply, regardless of cannabis stocks going up and down in slow regulatory phases, doctor awareness of opioid alternatives and demand is growing and only just starting.

It is our hope that this market insight will help investors gain an understanding of how ODI Pharma surveys the landscape of the industry.

COMMENTS BY CEO DEREK SIMMROSS



“I am delighted to say that we have started the new year with an important step forward with Project Poland. With our Marketing Authorization Holder application now approved, we can continue to work on getting all the necessary transit permits in place to begin our operations on the Polish market.”

As we have previously communicated, we have been working for the past two years to get our Marketing Authorization Holder application approved, it is therefore extremely gratifying that we have now received it and that we are now in a position where we have the right to carry out medical cannabis operations and upcoming business activities on the Polish market.

We have an already established cooperation with one of the leading pharmaceutical wholesales in Poland, NEUCA, and a supply contract with a wholly owned subsidiary of the largest cannabis producers in the world who is a first-tier producer operating at the highest standards. I am confident that this puts us in a very good position to take Project Poland forward. The market for medical cannabis in Poland has great potential and we look forward to ODI Pharma being able to help patients suffering from MS, epilepsy, and other diseases.

While much of our work is being put into Project Poland as it is our main focus, we continue to work on establishing our CBD-infused skincare brand kandol. on the European market under Project Skin. It is clear that the interest in cannabinoids in cosmetics is high and it is therefore important that we ensure that kandol. can be offered to the market through our collaborations with European retailers, skin clinics, pharmaceutical distribution platforms and online partners. We are also working to strengthen our social media presence to reach out to potential customers.

Finally, I would like to thank our shareholders who continue to follow our journey towards becoming a European leader in the pharmaceutical market for offering medical cannabis products and CBD-infused skin care products. Together, we now look forward to the development we have ahead of us in the second half of the financial year.

Derek Simmross

CEO, ODI Pharma AB

ABOUT ODI PHARMA

ODI Pharma, based on its European network, subsidiaries, and partners, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland.

ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. To achieve its goals, the Company are teaming up with the most knowledgeable and best renown partners in the industry to achieve its goals. The main focus of ODI Pharma is on the medical cannabis product that are sold to clients and patients through ODI Pharma's relationships with pharmacies via wholesale distributors. According to the Company, cosmetics is a perfect complementary addition to its pharmaceutical focus, allowing ODI Pharma to benefit from synergies and mutual benefits.

On the 24th of January 2023, ODI Pharma received the approval for the application to achieve a Marketing Authorization in Poland, this is the permit required to carry out medical cannabis operations and upcoming business activities in the Polish market. After the successful approval, ODI Pharma is now working diligently on the necessary import/export permits to begin operations in Poland. These permits are required for all regulated business in our industry, and it is what ODI Pharma sees as a standardized procedure to be implemented. This means that upon completion, ODI Pharma looks forward to being able to commence an additional operational business in the near future. ODI Pharma's Polish medical cannabis operations are carried out through its subsidiary on the Polish market, which handles the imports, distribution and supporting education for medical cannabis products. The Company has secured a relationship with one of the leading pharmaceutical wholesales in Poland, NEUCA. Further, the Company has secured a valuable subsidiary of the largest cannabis producer in the world. The supplier is a first-tier producer who operates at the highest standards.

ODI Pharma aims to become a leading supplier of medical cannabis on the Company's target markets in Europe. The European market for medical cannabis has the potential to become the world's largest market for medical cannabis. The Company believes that European clients require a wide variety of medical cannabis products of high quality to treat specific illnesses. The Company is a medical cannabis finished product producer and therefore has no cultivation operations, it has access to provide a wide variety of different strains, oils, and the latest formulations. The Company intends to provide a range of medical cannabis products which will initially, due to the regulation in Poland, be dried flowers.

The products

Medical cannabis

Medical cannabis comes in a range of different products with different levels of THC (Tetrahydrocannabinol) and CBD (Cannabidiol). The products that ODI Pharma is going to produce for the Polish market, per the *Polish Strategy*, are products that will be approved by the Polish governmental agencies. Initially, the products will be dried flowers, since this is the product that this far has been regulated in Poland (even though the law in Poland allows for a range of derivatives from the cannabis plant). These products will be based on the raw material of

fully approved cannabis imported by the Company and strategic partners. The dried flowers can be consumed by the patients in various ways following the guidelines of the pharmacists. ODI Pharma is evaluating other product types besides dried flowers to be sold on the Polish market. ODI Pharma is evaluating other product types besides dried flowers to be sold on the Polish market.

ODI Pharma intends to be up to date on trends and regulatory requirements and future products may, therefore, differ from the current products. The market demand decides what type of medical cannabis products the Company will supply, which the Company's flexible business model enables. The production of the products is fully integrated with NEUCA. The current market price of dried flowers in Poland is approx. EUR 13.00-16.00 (based on current exchange rate) per gram, ODI Pharma intends to at least match this price, while still providing high-quality products. Whatever product type of medical cannabis ODI Pharma provides, the objectives is to be cost-efficient concerning what has previously been stated.

Kandol.

At the beginning of 2021, ODI Pharma launched "Project Skin", to further build ODI Pharma's reputation and brand awareness on the European market. ODI Pharma believes that that CBD-infused cosmetics is a perfect complement to its pharmaceutical focus, allowing ODI Pharma to benefit from synergies and mutual benefits. On the 1st of October 2021, ODI Pharma officially launched the CBD-skincare product line, under the brand "kandol.". The Company's product line consists of CBD-infused facial cream, facial mask, and body balm with further products in development. The skincare brand is innovative and focuses of sustainable packaging, based on beauty and scientific knowledge. The product formulations and sustainable approach create a unique market position for ODI Pharma, targeting a small but considerably growing segment of the cannabis industry. The skincare line is suitable for all skin types and ages and the products follow the guidelines of the EU CosIng (EU's official database for cosmetic ingredients) and are designed to be antioxidant and antiseborrheic products that protect and nourish the skin.

ODI Pharma has been working diligently to build the social media presence and placing the products in store and with online partners within Europe. To date, we have an agreement with 80+ online partners. Multiple high-end retail partners in Germany and Poland, participated in high end cosmetic competitions with great success and had multiple articles and recommendations from fashion magazines such as Vogue. The next steps are to attract influencers and kandol. club partners to express the wonderful reviews to a broader client base.

Target groups

There is a total of about 40+ indications in which medical cannabis may potentially show results in terms of efficacy. The Supreme Pharmaceutical Chamber of Poland (Naczelna Izba Aptekarska) estimates an immediate market demand of 300,000 patients by 2025. Jędrzej Sadowski, the author of the bill legalizing cannabis, estimates 300,000 patients as well. ODI Pharma assumes that it will take some years to reach the potential patients' number that uses the product, and the Company estimates that this will be reached in 2025. The Polish regulations do not limit the prescriptions for medical cannabis concerning certain ailments – therefore all physicians have the authorization to prescribe medical cannabis to all their patients and all types of illnesses. The Supreme Pharmaceutical Chamber of Poland suggested the application with treatable conditions including nausea caused by chemotherapy, epilepsy, symptoms of multiple sclerosis, and chronic pain.

ABOUT THE HALF-YEAR REPORT

Group structure

ODI Pharma AB was formed on the 23rd of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG (100 %). ODI Pharma Schweiz AG has an ownership of 100 % in ODI Pharma Polska Sp. z o.o. The group was established on the 28th of June 2018 (the "Group") when ODI Pharma Schweiz AG acquired the shares in ODI Pharma Polska Sp. z o.o.

Revenue and operating results Q2

The Group's revenue amounted to SEK 80,524 (516,768) in the second quarter and resulted in an operating income of SEK -1,707,658 (-1,390,351). A majority of the operating expenses are related to insurance expenses, legal services, procurement of raw materials and products, salaries to salesperson, audit services, and accounting services. The holding company, ODI Pharma AB, has generated revenues of SEK 80,213 (468,169) during the second quarter.

Balance sheet and solidity

ODI Pharma AB was registered with the Swedish Companies Registration Office on the 23rd of October 2019 with shareholder equity of SEK 500,000. The Company has no long-term liabilities. The group was established on the 28th of June 2018. Total assets of the Group amounted to SEK 7,751,716 (14,834,629) and consisted primarily of cash and cash equivalents. The solidity of the Group was 81% (93%) at quarter-end. The holding company, ODI Pharma AB, stated total assets of SEK 7,830,703 (14,487,054) consisting primarily of cash and cash equivalents. The solidity of ODI Pharma AB was 66% (93%).

Cash flow and investments

Cash flow from operations in the Group during the second quarter amounted to SEK -1,738,790 (-1,396,740). Cash flow from financing and investment activities during the second quarter amounted to SEK 0 (38), resulting in cash flow from July 2022 to December 2022 of SEK -2,569,110 (-3,915,779). The holding company, ODI Pharma AB, showed a cash flow for the period (after financing and investment activity) of SEK -1,148,811 (-3,209,265) during the second quarter.

The share

The shares of ODI Pharma were listed on Spotlight Stock Market on the 23rd of January 2020. The short name/ticker is ODI and the ISIN code is SE0013409760. Spotlight Stock Market operates a so-called MTF platform and is a secondary name of ATS Finans AB, a securities company under the supervision of the Swedish Financial Supervisory Authority. ATS Finans AB is a subsidiary of Spotlight Group AB, a company listed on Spotlight Stock Market since the 15th of September 2020. On the 31st of December 2022, the number of shares in ODI Pharma amounted to 15,220,000 (15,220,000). The average number of shares during the second quarter amounted to 15,220,000 (15,220,000). Every share equals the same rights to the Company's assets and results.

Warrants

No warrants are outstanding to any party.

Financial calendar

July 2022 – March 2023 (Q3)

25th of May 2023

Shareholders

The table below presents the current shareholders, as of 31st of December 2022, with more than 5 percent of the votes and capital in ODI Pharma AB.

Name	Number of shares	The proportion of votes and capital (%)
Volker Wiederrich	6,255,898	41.10
Derek Simmross	6,250,000	41.06
Niclas Kappelin	1,133,000	7.73
<i>Other shareholders (approx. 1,200)</i>	<i>1,581,102</i>	<i>10.11</i>
Total	15,220,000	100.00

Auditor's review

The half-year report has not been reviewed by the Company's auditor.

Accounting policy of the quarterly report

The financial statements of ODI Pharma AB, as well as the ODI Pharma Group, are prepared per the Swedish Annual Accounts Act and the standards of the Swedish Accounting Standards Board (BFNAR) 2012:1 (K3) and Spotlight Stock Market's Rules and Regulations, as applicable. Consolidated accounts include parent company and subsidiaries in which the parent company directly or indirectly owns shares that are more than 50 % of the votes. Intangible and tangible assets are at the acquisition value reduced with accumulated depreciation according to plan and eventually write-downs. Depreciation is done linearly in relation to expected useful life. The financial overviews of ODI Pharma's subsidiaries were prepared in the local currency (CHF for the Swiss subsidiary and PLN for the Polish subsidiary). For this report, the local currencies have been recalculated to SEK in the financial overview, based on data from Sveriges Riksbank on the 31st of December 2022, respectively the average exchange rate for the presented time frame.

Common Control Transaction

During the financial year 2019/2020, ODI Pharma AB acquired ODI Pharma Schweiz AG from the previous owners through a related party transaction. The acquisition was carried out through a promissory note of CHF 100,000, which, in accordance with an established agreement, was subject to set-off in connection with a new issue using the K3 currency conversion principle. K3 does not comment on common control transactions and in the absence of guidance, the Company has chosen to report the transaction based on the former group's book values, since the newly formed company is not considered an acquirer in the transaction. This means that ODI Pharma Sweden AB's consolidated accounts are a continuation of what was previously reported in the ODI Pharma Switzerland Group and the comparative figures presented are the ODI Pharma Switzerland Group's financial information for 2018, adjusted for differences in accounting principles.

Operational risks and uncertainties

As announced via press release the Board of Directors did not see any impact on the Company's mid- and long-term goals due to COVID-19. Today, the Company does not foresee any potential further consequences for the

business, but it cannot be predicted if future problem may arise which may influence the business. The Company will continue to follow developments.

The risks and uncertainties that ODI Pharma's operations are exposed to are summaries related to factors such as development, competition, permissions, capital requirements, customers, suppliers/manufacturers, currencies, and interest rates.

Submission of the half-year report

Stockholm, 23rd of February 2023

ODI Pharma AB

The Board of Directors

For further information, please contact

Derek Simmross, CEO

E-mail: info@odipharma.com

Website: <https://www.odipharma.com/>

ODI Pharma AB was formed on the 23rd of October 2019. ODI Pharma AB is the Swedish holding company of ODI Pharma Schweiz AG and ODI Pharma Polska Sp. z o.o. The group was established on the 28th of June 2018.

INCOME STATEMENT – THE GROUP

SEK	2022-10-01 2022-12-31 3 months	2021-10-01 2021-12-31 3 months	2022-07-01 2022-12-31 6 months	2021-07-01 2021-12-31 6 months	2021-07-01 2022-06-30 12 months
Revenue					
Net sales	73,276	458,620	101,282	458,620	312,938
Other operating income	7,249	58,148	25,104	58,465	87,871
	80,524	516,768	126,386	517,085	400,809
Operating expenses					
Cost of goods sold	-33,636	-571,481	-136,495	-571,481	-416,575
External expenses	-1,627,213	-963,677	-2,814,160	-1,791,544	-5,495,005
Personal expenses	-127,570	-343,103	-404,160	-669,805	-1,625,866
Depreciation and amortisation	-1,017	-1,367	-2,015	-2,695	-5,588
Other operating expenses	-1,254	-27,493	-46,017	-38,766	-64,676
Total operating cost	-1,788,182	-1,907,120	-3,402,847	-3,074,290	-7,607,710
Operating income	-1,707,658	-1,390,351	-3,276,461	-2,557,204	-7,206,901
Profit/loss from financial items					
Other interest income and similar profit/loss items	4,719	1,705	4,719	4,986	133
Interest expense and similar profit/loss items	-32,492	-12,856	-148,200	-24,672	-28,762
Income after financial items	-1,735,431	-1,401,502	-3,419,942	-2,576,890	-7,235,530
Income before taxes	-1,735,431	-1,401,502	-3,419,942	-2,576,890	-7,235,530
Taxes	-389	-3,365	-4,208	-3,393	-3,508
Net income	-1,735,820	-1,404,867	-3,424,150	-2,580,283	-7,239,038
<i>Number of shares in the beginning of the period</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Number of shares at the end of the period</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Average number of shares</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Earnings per share, SEK</i>	-0.11	-0.09	-0.22	-0.17	-0.48

BALANCE SHEET – THE GROUP

SEK	2022-12-31	2021-12-31	2022-06-30
Assets			
Fixed assets			
<i>Tangible fixed assets</i>			
Equipment, machines, tools	10,919	14,141	12,309
	10,919	14,141	12,309
Total fixed assets	10,919	14,141	12,309
Current assets			
Inventories			
Raw materials and consumables	348,695	470,694	348,695
Finished goods and goods for resale	1,163,093	1,159,628	1,202,490
Advance payments to supplier	188,050	700,999	188,050
	1,699,838	2,331,321	1,739,235
Current receivables			
Trade receivables	122,223	467,503	108,628
Tax receivables	280,437	210,698	228,853
Other current receivables	527,385	840,603	757,372
Prepaid expenses and accrued income	130,985	248,268	282,744
	1,061,030	1,767,073	1,377,597
Cash and cash equivalents	4,979,929	10,736,094	7,367,789
Total current assets	7,740,797	14,834,488	10,484,621
TOTAL ASSETS	7,751,716	14,848,629	10,496,930

SEK	2022-12-31	2021-12-31	2022-06-30
EQUITY AND LIABILITIES			
Equity			
Share capital	608,800	608,800	608,800
Other contributed capital	22,168,101	21,952,268	22,168,100
Other equity including result for the period	-16,478,536	-8,739,543	-13,515,591
Equity attributed to shareholders in parent company	6,298,365	13,821,525	9,261,309
Current liabilities			
Account payables	1,136,938	810,980	674,809
Tax liabilities	3,952	0	0
Other current liabilities	76,289	77,328	7,681
Accrued expenses and prepaid income	236,171	138,796	553,131
Total current liabilities	1,453,351	1,027,104	1,235,621
TOTAL EQUITY AND LIABILITIES	7,751,716	14,848,629	10,496,930

CASH FLOW STATEMENT – THE GROUP

SEK	2022-10-01	2021-10-01	2022-07-01	2021-07-01	2021-07-01
	2022-12-31	2021-12-31	2022-12-31	2021-12-31	2022-06-30
	3 months	3 months	6 months	6 months	12 months
Operating activities					
Net operating profit/loss	-1,741,180	-1,390,351	-3,424,150	-2,557,204	-7,206,901
<i>Adjustment for non-cash flow items</i>					
Depreciations and write-downs	1,017	1,367	2,035	2,695	5,588
Current exchange differences	1,373	7,756	26,166	-10,204	50,461
Other items not affecting cash flow	0	0	0	0	0
Cash flow from operating activities	-1,738,790	-1,396,740	-3,395,949	-2,564,712	-7,150,852
Paid interest	10,113	-1,082	4,526	-2,062	-234
Paid tax	0	10,424	36,052	-903	-32,497
Cash flow from operation before change in working capital	-1,728,676	-1,387,398	-3,355,371	-2,567,677	-7,183,583
<i>Cash flow from change in working capital</i>					
Change in inventories and ongoing works	-16,364	-507,849	39,398	-1,281,787	-689,700
Increase (-) Decrease (+) of operating receivables	169,858	-689,588	-1,151,038	-273,091	-154,955
Increase (+) Decrease (-) of operating liabilities	342,067	147,832	1,897,902	202,800	653,895
Total change in working capital	-1,233,114	-2,437,003	-2,569,109	-3,919,754	-7,374,343
Investment activities					
Investments in tangible fixed assets	0	38	0	3,975	4,109
Cash flow from investment activities	0	38	0	3,975	4,109
Financing activities					
New share issue	0	0	0	0	0
New share issue expenses	0	0	0	0	0
Cash flow from financing activities	0	0	0	0	0
Cash flow for the period	-1,233,114	-2,436,966	-2,569,110	-3,915,779	-7,370,234
Cash and cash equivalents at beginning of year	6,223,677	13,148,270	7,367,789	14,628,837	14,624,893
Effects of exchange rate changes on cash	-10,634	24,791	181,251	23,039	113,130
Cash and cash equivalents at end of year	4,979,929	10,736,094	4,979,929	10,736,096	7,367,789

INCOME STATEMENT – ODI PHARMA AB

SEK	2022-10-01	2021-10-01	2022-07-01	2021-07-01	2021-07-01
	2022-12-31	2021-12-31	2022-12-31	2021-12-31	2022-06-30
	3 months	3 months	6 months	6 months	12 months
Revenue					
Net sales	72,964	458,620	97,172	458,620	295,986
Other operating income	7,249	9,549	25,104	9,735	46,162
	80,213	468,169	122,276	468,355	342,148
Operating expenses					
Cost of goods sold	-33,636	-531,531	-89,397	-531,531	-341,078
External expenses	-1,788,083	-1,030,505	-3,132,613	-1,980,570	-5,822,289
Personal expenses	-92,661	-310,013	-366,962	-636,715	-1,591,647
Depreciation and amortisation	0	0	0	0	0
Other operating expenses	-1,402	-29,642	-46,845	-36,740	-59,750
Total operating cost	-1,915,782	-1,901,690	-3,635,817	-3,185,555	-7,814,764
Operating income	-1,835,569	-1,433,521	-3,513,541	-2,717,200	-7,472,616
Income from financial items					
Other interest income and similar profit/loss items	4,719	1,706	4,719	4,986	0
Interest expense and similar profit/loss items	-194	0	-194	0	-6,825
Income after financial items	-1,831,044	-1,431,815	-3,509,016	-2,712,214	-7,479,441
Income before taxes	-1,831,044	-1,431,815	-3,509,016	-2,712,214	-7,479,441
Taxes	0	0	0	0	0
Net income	-1,831,044	-1,431,815	-3,509,016	-2,712,214	-7,479,441
<i>Number of shares in the beginning of the period</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Number of shares at the end of the period</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Average number of shares</i>	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00	15,220,000.00
<i>Earnings per share, SEK</i>	-0.12	-0.09	-0.23	-0.18	-0.49

BALANCE SHEET – ODI PHARMA AB

SEK	2022-12-31	2021-12-31	2022-06-30
ASSETS			
Fixed assets			
<i>Financial fixed assets</i>			
Participations in groups companies	967,200	967,200	967,200
	967,200	967,200	967,200
Total fixed assets	967,200	967,200	967,200
Current assets			
Inventories			
Raw materials and consumables	348,695	470,694	348,695
Finished goods and goods for resale	1,163,093	1,159,628	1,202,490
Advance payments to suppliers	188,050	700,999	188,050
	1,699,838	2,331,321	1,739,235
Current receivables			
Trade receivables	54,486	419,989	44,709
Receivables in group companies	0	33,774	
Other current receivables	431,329	584,438	633,330
Prepaid expenses and accrued income	864,434	873,315	436,063
	1,350,249	1,911,516	1,114,102
Cash and cash equivalents	3,813,416	9,277,017	5,932,603
Total current assets	6,863,503	13,519,854	8,785,940
TOTAL ASSETS	7,830,703	14,487,054	9,753,140

SEK

2022-12-31

2021-12-31

2022-06-30

EQUITY AND LIABILITIES**Equity***Restricted reserves*

Share capital	608,800	608,800	608,800
---------------	---------	---------	---------

Non-restricted reserves

Share premium reserve

<i>Share premium</i>	21,472,267	21,472,267	21,472,267
----------------------	------------	------------	------------

Retained earnings

	-13,378,611	-5,899,170	-5,899,171
--	-------------	------------	------------

Profit or loss for period

	-3,509,015	-2,712,214	-7,479,441
--	------------	------------	------------

Total equity	5,193,441	13,459,683	8,702,455
---------------------	------------------	-------------------	------------------

Current liabilities

Account payables	892,064	746,070	475,359
------------------	---------	---------	---------

Liabilities to group companies	1,177,554	111,999	76,194
--------------------------------	-----------	---------	--------

Other current liabilities	76,194	77,328	7,681
---------------------------	--------	--------	-------

Accrued expenses and prepaid income	491,451	81,974	491,451
-------------------------------------	---------	--------	---------

Total current liabilities	2,637,262	1,017,371	1,050,685
----------------------------------	------------------	------------------	------------------

TOTAL EQUITY AND LIABILITIES	7,830,703	14,487,054	9,753,140
-------------------------------------	------------------	-------------------	------------------

CASH FLOW STATEMENT – ODI PHARMA AB

SEK	2022-10-01 2022-12-31 3 months	2021-10-01 2021-12-31 3 months	2022-07-01 2022-12-31 6 months	2021-07-01 2021-12-31 6 months	2021-07-01 2022-06-30 12 months
Operating activities					
Net operating profit/loss	-1,835,569	-1,433,520	-3,513,542	-2,717,200	-7,472,616
<i>Adjustment for non-cash flow items</i>					
Depreciations and write-downs	0	0	0	0	0
Current exchange differences	0	1,703	0	-4,984	0
Other items not affecting cash flow	0	0	0	0	-2
Cash flow from operating activities	-1,835,569	-1,431,817	-3,513,542	-2,712,216	-7,472,618
Paid interest	4,526	0	4,526	0	-123
Paid tax	0	0	0	0	0
Cash flow before change in working capital	-1,831,043	-1,431,817	-3,509,016	-2,712,216	-7,472,741
<i>Cash flow from change in working capital</i>					
Change in inventories and ongoing works	-16,364	-507,849	39,398	-1,281,787	-689,700
Increase (-) Decrease (+) of operating receivables	148,711	-452,053	14,011	-990,870	-193,456
Increase (+) Decrease (-) of operating liabilities	549,885	-817,546	1,336,420	476,618	509,931
Total change in working capital	-1,148,811	-3,209,265	-2,119,187	-4,508,255	-7,845,966
<i>Investment activities</i>					
Investments in tangible fixed assets	0	0	0	0	0
Cash flow from investment activities	0	0	0	0	0
<i>Financing activities</i>					
New shares issue	0	0	0	0	0
New share issue expenses	0	0	0	0	0
Cash from financing activities	0	0	0	0	0
Cash flow for the period	-1,148,811	-3,209,265	-2,119,187	-4,508,255	-7,845,966
Cash and cash equivalents at the beginning of year	4,962,227	12,486,281	5,932,603	13,785,271	13,785,271
Effects of exchange rate changes on cash	0	0	0	0	-6,702
Cash and cash equivalents at the end of year	3,813,416	9,277,016	3,813,416	9,277,016	5,932,603



ODI Pharma

www.odipharma.com